vedomostiregmedРегуляторные исследования и экспертиза лекарственных средствRegulatory Research and Medicine Evaluation3034-30623034-3453Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)vedomostiregmed-10Research ArticleДОКЛИНИЧЕСКОЕ И КЛИНИЧЕСКОЕ ИЗУЧЕНИЕ ЛЕКАРСТВЕННЫХ СРЕДСТВPRECLINICAL AND CLINICAL STUDY OF MEDICINESТест-система для оценки активности ингибиторов GSK-3 в качестве антигипоксантов и индукторов дифференцировки эндотелиальных предшественников in vitroTest-system for the assessment of GSK-3 inhibitors activity as antihypoxants and endothelial differentiation stimulators in vitroБурдаЮ. Е.BurdaYu. E.noemail@neicon.ruНадеждинС. В.NadezhdinS. V.noemail@neicon.ruЗубареваЕ. В.ZubarevaE. V.noemail@neicon.ruПокровскийМ. В.PokrovskyM. V.noemail@neicon.ruБурдаС. Ю.BurdaS. Yu.noemail@neicon.ruШиринаМ. С.ShirinaM. S.noemail@neicon.ruНациональный исследовательский университет «Белгородский государственный университет»РоссияBelgorod State National Research UniversityRussian FederationКурский государственный медицинский университетРоссияKursk State Medical UniversityRussian Federation201613022018012932Copyright © Бурда Ю.Е., Надеждин С.В., Зубарева Е.В., Покровский М.В., Бурда С.Ю., Ширина М.С., 20182018Бурда Ю.Е., Надеждин С.В., Зубарева Е.В., Покровский М.В., Бурда С.Ю., Ширина М.С.Burda Y.E., Nadezhdin S.V., Zubareva E.V., Pokrovsky M.V., Burda S.Y., Shirina M.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.vedomostincesmp.ru/jour/article/view/10

Описаны этапы разработки модельной тест-системы для проверки in vitro антигипоксической и эндотелиально-дифференцировочной активности вновь создаваемых ингибиторов киназы гликогенсинтазы-3 - потенциальных регуляторов клеточной активности. В качестве референтного препарата выбран β4-тимозин, обладающий противоишемическим и ангиогенным действием. Предложенная экспериментальная клеточная модель может быть использована в предварительном тестировании новых химических соединений в плане их лекарственного потенциала при ишемических расстройствах и быть альтернативой методикам с использованием лабораторных животных.

The present article describes the stages of the development of the test-system that allows to research the potency of GSK-3 inhibitors to induce endothelial progenitor differentiation and to increase cell survival in hypoxia in vitro. β4-thymosin, which shows anti-ischemic and angiogenic activity, has been used a reference preparation. The proposed experimental cell model can be useful in the preliminary testing of new chemical compounds in terms of their ability to treat ischemic disorders and it can be used as an alternative for procedures involving animal testing.

киназа гликогенсинтазы-3GSK-3β4-тимозингипоксияишемияэндотелийGlycogen synthase kinase 3GSK-3β4-thymosinhypoxiaischemiaendotheliumReferencesОсолодкин ДИ. Молекулярный дизайн потенциальных ингибиторов киназы гликогенсинтазы 3: дис. … канд. хим. наук. М.; 2011.Osolodkin DI. Molecular design of potential glycogen synthase kinase 3 inhibitors: Dr. Chem. Sci [dissertation]. Moscow; 2011 (in Russian).Шаманская ТВ, Осипова ЕЮ, Румянцев СА. Ex vivo экспансия гемопоэтических стволовых клеток пуповинной крови (обзор литературы). Онкогематология 2012; (1): 35-44.Shamanskaya TV, Osipova EYu, Rumyantsev SA. Ex vivo expansion of cord blood-derived hemopoietic stem cells (review). Onkogematologiya 2012; (1): 35–44 (in Russian).Xu TJ, et al. A novel dimeric thymosin beta 4 with enhanced activities accelerates the rate of wound healing. Drug Design, Development and Therapy 2013; 7: 1075-88.Xu TJ, et al. A novel dimeric thymosin beta 4 with enhanced activities accelerates the rate of wound healing. Drug Design, Development and Therapy 2013; 7: 1075–88.Chang Z-T, et al. Application of peripheral-blood-derived endothelial progenitor cell for treating ischemia-reperfusion injury and infarction: a preclinical study in rat models. Journal of Cardiothoracic Surgery 2013; 8: 33-43.Chang Z-T, et al. Application of peripheral-blood-derived endothelial progenitor cell for treating ischemia-reperfusion injury and infarction: a preclinical study in rat models. Journal of Cardiothoracic Surgery 2013; 8: 33–43.Yanbo Z,β4 activates integrin-linked kinase and decreases endothelial progenitor cells apoptosis under serum deprivation. Journal of Cellular Physiology 2011; 226: 2798-2806.Yanbo Z, et al. Thymosin 4 activates integrin-linked kinase and decreases endothelial progenitor cells apoptosis under serum deprivation. Journal of Cellular Physiology 2011; 226: 2798–2806.Hinkel R, et al. Thymosin β4 Is an Essential Paracrine Factor of Embryonic Endothelial Progenitor Cell-Mediated Cardioprotection. Circulation 2008; 117: 2232-40.Hinkel R, et al. Thymosin 4 Is an Essential Paracrine Factor of Embryonic Endothelial Progenitor Cell-Mediated Cardioprotection. Circulation 2008; 117: 2232–40.Nana Y. The characteristics of endothelial progenitor cells derived from mononuclear cells of rat bone marrow in different culture conditions. Cytotechnology 2011; 63: 217-26.Nana Y. The characteristics of endothelial progenitor cells derived from mononuclear cells of rat bone marrow in different culture conditions. Cytotechnology 2011; 63: 217–26.Miura T, Nishihara M, Miki T. Drug Development Targeting the Glycogen Synthase Kinase-3β (GSK-3β)-Mediated Signal Transduction Pathway: Role of GSK-3β in Myocardial Protection Against Ischemia/Reperfusion Injury. J Pharmacol Sci. 2009; 109: 162-67.Miura T, Nishihara M, Miki T. Drug Development Targeting the Glycogen Synthase Kinase-3 (GSK-3)-Mediated Signal Transduction Pathway: Role of GSK-3 in Myocardial Protection Against Ischemia/Reperfusion Injury. J Pharmacol Sci. 2009; 109: 162–67.Marx U, Sandig V, eds. Drug Testing In Vitro. WILEY-VCH; 2007.Marx U, Sandig V, eds. Drug Testing In Vitro. WILEY-VCH; 2007.

The authors declare that there are no conflicts of interest present.